BRPI0409652A - tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete - Google Patents

tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete

Info

Publication number
BRPI0409652A
BRPI0409652A BRPI0409652-5A BRPI0409652A BRPI0409652A BR PI0409652 A BRPI0409652 A BR PI0409652A BR PI0409652 A BRPI0409652 A BR PI0409652A BR PI0409652 A BRPI0409652 A BR PI0409652A
Authority
BR
Brazil
Prior art keywords
tablet
disease treatment
pharmaceutical packaging
coating
treatment method
Prior art date
Application number
BRPI0409652-5A
Other languages
English (en)
Inventor
Guy Vergnault
Pascal Grenier
Christophe Dragan
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409652(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of BRPI0409652A publication Critical patent/BRPI0409652A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"TABLETE, EMBALAGEM FARMACêUTICA, MéTODO DE TRATAMENTO DE DOENçAS, E, MéTODO DE PREPARAçãO DE UM TABLETE". A invenção refere-se um tablete que compreende um núcleo contendo uma substância de droga, e um revestimento, o núcleo sendo disposto dentro do dito revestimento de tal forma que o revestimento tenha uma primeira espessura em torno de um eixo (A - B) e uma espessura em torno de um eixo (X - Y), de tal forma que o revestimento em torno do eixo (X - Y) seja maior que o revestimento em torno do ao eixo (A - B), e é adaptado para fornecer um tempo de atraso entre cerca de 2 a cerca de 6 horas durante o qual substancialmente nenhuma droga é liberada.
BRPI0409652-5A 2003-04-24 2004-04-23 tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete BRPI0409652A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309342 2003-04-24
PCT/IB2004/001693 WO2004093843A1 (en) 2003-04-24 2004-04-23 Delayed release tablet with defined core geometry

Publications (1)

Publication Number Publication Date
BRPI0409652A true BRPI0409652A (pt) 2006-04-25

Family

ID=33306519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409652-5A BRPI0409652A (pt) 2003-04-24 2004-04-23 tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete

Country Status (20)

Country Link
US (6) US8168218B2 (pt)
EP (1) EP1631251B1 (pt)
JP (1) JP4790597B2 (pt)
KR (1) KR101192722B1 (pt)
CN (2) CN1777412A (pt)
AT (1) ATE512659T1 (pt)
AU (1) AU2004231362B2 (pt)
BR (1) BRPI0409652A (pt)
CA (1) CA2523158C (pt)
CY (1) CY1111835T1 (pt)
DK (1) DK1631251T3 (pt)
ES (1) ES2368066T3 (pt)
IL (1) IL171494A (pt)
MX (1) MXPA05011446A (pt)
PL (1) PL1631251T3 (pt)
PT (1) PT1631251E (pt)
RU (1) RU2391093C2 (pt)
SI (1) SI1631251T1 (pt)
WO (1) WO2004093843A1 (pt)
ZA (1) ZA200509477B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
SI1631251T1 (sl) 2003-04-24 2011-10-28 Jagotec Ag Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra
ES2335008T3 (es) * 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
ZA200802602B (en) * 2005-08-24 2009-10-28 Rubicon Res Pvt Ltd Controlled release formulation
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
PT2049123E (pt) * 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
CA2672602C (en) 2006-12-18 2014-05-20 Electronic Dietary Foods Inc. Device for delivery of a substance
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US10363221B2 (en) * 2007-10-17 2019-07-30 I-Property Holding Corp. Manufacturing solid pharmaceutical dosage forms with visible micro- and nanostructured surfaces and micro- and nanostructured pharmaceutical dosage form
US20090214599A1 (en) * 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
EP2651399A2 (en) 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
WO2013030726A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Programmed drug delivery
RU2471479C1 (ru) * 2012-02-13 2013-01-10 Общество с ограниченной ответственностью "Агентство редких лекарств и технологий" Фармацевтическая композиция в форме таблетки для перорального введения, содержащая в качестве активного компонента дексаметазон, и способ ее получения
US20130243861A1 (en) * 2012-03-16 2013-09-19 Cadila Healthcare Limited Press-coated tablets of prednisone
JP5818219B2 (ja) * 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
GB201420306D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
WO2016114726A1 (en) * 2015-01-12 2016-07-21 Ilko Ilaç Sanayi Ve Ticaret Anonim Şirketi Time-controlled prednisone delayed release tablet
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
EP3558300B1 (en) * 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
CN115297848B (zh) * 2020-03-31 2024-11-15 江苏恒瑞医药股份有限公司 一种非布司他片
CN114588124B (zh) * 2020-12-07 2023-10-20 江苏恒瑞医药股份有限公司 一种延迟释放的药物组合物
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease
CN121335697A (zh) * 2023-06-14 2026-01-13 吉纳斯生命科学公司 包括苯巴比妥的药物口服固体剂型及其制造和使用方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874586A (en) 1957-10-28 1961-08-10 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
HU219341B (en) 1990-07-02 2001-03-28 Roche Diagnostics Gmbh Process for producing pressed, moulded, delayed release dose units and dose units thus produced
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
ES2060465T3 (es) 1991-01-03 1994-11-16 Glaxo Canada Procedimiento para la produccion de preparacion farmaceutica solida.
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
WO1993019741A1 (en) * 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
JPH07507564A (ja) 1992-09-30 1995-08-24 ファイザー・インク． コア及び厚さが一定でないコーティングを含有する物品
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5567969A (en) * 1995-04-20 1996-10-22 Hall; John H. Compound modulated integrated transistor structure with reduced bipolar switch back effect
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
DE69814122T2 (de) 1997-10-09 2004-03-18 Dexcel Pharma Technologies Ltd. Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
KR20040047747A (ko) * 2001-03-13 2004-06-05 펜웨스트 파머슈티칼즈 컴파니 변시치료 제형
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
RU2187307C1 (ru) * 2001-10-15 2002-08-20 Сыров Кирилл Константинович Твердые стабильные лекарственные формы преднизолона
KR20040091135A (ko) 2002-03-14 2004-10-27 다이이찌 산토리 파마 가부시키가이샤 염산 필지카이니드 함유 정제(건식)
EP1542662A1 (en) 2002-09-28 2005-06-22 McNEIL-PPC, INC. Immediate release dosage form comprising shell having openings therein
SI1631251T1 (sl) * 2003-04-24 2011-10-28 Jagotec Ag Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra
ES2335008T3 (es) 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
WO2005027843A2 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum

Also Published As

Publication number Publication date
SI1631251T1 (sl) 2011-10-28
US20120177739A1 (en) 2012-07-12
US20140328912A1 (en) 2014-11-06
US20160256396A1 (en) 2016-09-08
US20070110807A1 (en) 2007-05-17
IL171494A (en) 2011-04-28
CN102525993A (zh) 2012-07-04
AU2004231362A1 (en) 2004-11-04
PT1631251E (pt) 2011-09-19
KR101192722B1 (ko) 2012-10-18
CA2523158C (en) 2010-11-16
CN102525993B (zh) 2017-04-12
CY1111835T1 (el) 2015-10-07
US8168218B2 (en) 2012-05-01
PL1631251T3 (pl) 2011-12-30
RU2005132451A (ru) 2006-06-10
EP1631251A1 (en) 2006-03-08
DK1631251T3 (da) 2011-10-03
ES2368066T3 (es) 2011-11-14
US20120177734A1 (en) 2012-07-12
US8394407B2 (en) 2013-03-12
ZA200509477B (en) 2006-09-27
CN1777412A (zh) 2006-05-24
US9186332B2 (en) 2015-11-17
WO2004093843A1 (en) 2004-11-04
US9884021B2 (en) 2018-02-06
AU2004231362B2 (en) 2009-11-12
US9040085B2 (en) 2015-05-26
ATE512659T1 (de) 2011-07-15
US20130122061A1 (en) 2013-05-16
KR20060015528A (ko) 2006-02-17
CA2523158A1 (en) 2004-11-04
RU2391093C2 (ru) 2010-06-10
US8309124B2 (en) 2012-11-13
EP1631251B1 (en) 2011-06-15
JP4790597B2 (ja) 2011-10-12
JP2006524229A (ja) 2006-10-26
MXPA05011446A (es) 2006-05-31

Similar Documents

Publication Publication Date Title
ATE512659T1 (de) Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
ATE380022T1 (de) Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
AP1748A (en) Chronotherapeutic dosage forms.
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
ATE241357T1 (de) Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung
BR0313627A (pt) Formulações farmacêuticas, processos para a preparação de formulação farmacêutica e método para o tratamento de dores
DE60217121D1 (de) Medikament enthaltender klebstoff
DE59802670D1 (de) Osmotisches arzneimittelfreisetzungssystem
TW200602085A (en) Controlled-release pharmaceutical composition and method for producing same
NO20035655L (no) Fremgangsmate for fremstilling av tabletter
ATE391496T1 (de) Geschmacksmaskierte pharmazeutische formulierungen
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
WO2005027843A3 (en) Chronotherapeutic dosage forms
MA27320A1 (fr) Medicament contenant du trihydrate d'hydrochlorure de vardenfil
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
SE9700885D0 (sv) New pharmaceutical formulation
FR2816507B1 (fr) Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules
TW200517146A (en) Novel composition
AP1736A (en) Oral dosage form for controlled drug release.
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
ATE328587T1 (de) Feste pharmazeutische zusammensetzung enthaltend tilidinhydrochlorid
EP1693062A3 (en) Androgen receptor-dependent gene expression control
ITUD20030196A1 (it) Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/00; A61P 29/00

Ipc: A61K 9/00 (2011.01), A61P 29/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]

Free format text: ELIMINAR ALGUMAS REIVINDICACOES, OUTROS

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]